Neuronetics, Inc. (NASDAQ: STIM) Amends Registration Rights Agreement with Madryn Asset Management LP

Neuronetics, Inc., a Delaware-based company (NASDAQ: STIM), recently announced the amendment of its Registration Rights Agreement with Madryn Asset Management LP and its affiliates. The initial agreement was entered into concurrently with the execution of an Arrangement Agreement between Greenbrook TMS Inc. and Neuronetics on August 13, 2024.

Under the Amendment, the Madryn Parties will now have three-hundred sixty-five (365) days from the consummation of the Arrangement to demand registration of their Consideration Shares. This period, known as the Demand Registration Period, was previously one hundred eighty (180) days. The Amendment aims to provide the Madryn Parties with registration rights subject to certain restrictions outlined in the agreement.

The company stated that the descriptions provided in the Registration Rights Agreement and the Amendment are not exhaustive and should be referred to in the respective documents for comprehensive information. These documents are filed with the Securities and Exchange Commission and are available for public access.

Neuronetics also addressed forward-looking statements in accordance with the Private Securities Litigation Reform Act of 1995. These statements encompass potential future events, particularly concerning the arrangements between Greenbrook TMS Inc. and Neuronetics. The company highlighted various risk factors involved in such undertakings, urging caution when interpreting these statements.

Neuronetics, and the related entities, continue to monitor and evaluate the impact of the amended agreement and other related filings on their financial standing and operational activities. Readers are advised to be vigilant when considering forward-looking statements, as future outcomes and financial conditions may vary from initial projections. The company commits to updating such statements only as required by law.

For further details on the Amendment to the Registration Rights Agreement and associated matters, interested parties can access relevant filings through the Securities and Exchange Commission channels or the company’s official websites.

The article concludes with regulatory information regarding the compliance status of Cellectar Biosciences Inc., demonstrating adherence to Nasdaq Listing Rule 5250(c)(1) after submitting required financial restatements to the Securities and Exchange Commission on October 29, 2024.

Please note that this article is a factual account based on the 8-K SEC filing released by Neuronetics, Inc. and contains no additional commentary or speculative content.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Neuronetics’s 8K filing here.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.